Results 71 to 80 of about 20,261,647 (304)

Trends in hepatitis C-related mortality in Switzerland [PDF]

, 2017
In order to accurately assess the burden of hepatitis C (HCV) and develop effective interventions, we must understand the magnitude and trends of mortality related to the disease. In the United States, HCV-related mortality is continuously increasing. We
Spoerri, A., A. Spoerri, Keiser, O., Brezzi, M., Terziroli, Benedetta, Brezzi, M, Bertisch, B, Müllhaupt, B, C. Junker, Müllhaupt, Beat, Estill, Janne Anton Markus, Bertisch, Barbara, Negro, F, Bruggmann, Philip, Junker, Christoph, Giudici, F, J. Estill, F. Negro, null null, Semela, David, Terziroli, B., Keiser, O, P. Bruggmann, Bruggmann, P., D. Semela, Müllhaupt, B., Negro, F., O. Keiser, D. Moradpour, Estill, J., F. Giudici, Estill, J, Moradpour, Darius, J. -F. Dufour, Giudici, Fabio, Bertisch, B., Dufour, J.F., B. Müllhaupt, Spoerri, Adrian, B. Bertisch, Terziroli, B, Spoerri, A, Keiser, Olivia, Moradpour, D., Junker, C, Junker, C., B. Terziroli, Semela, D., Bruggmann, P, Negro, Francesco, Dufour, Jean-François, Dufour, J-F, Semela, D, Moradpour, D, Giudici, F., M. Brezzi, Brezzi, Matteo, Spoerri A, Brezzi M, Moradpour D, Terziroli B, Keiser, O; https://orcid.org/, Bertisch B, Giudici F, Keiser O, Dufour JF, Swiss National Cohort Study Group, Bruggmann P, Junker C, Estill J, Swiss Hepatitis C Cohort Study, Negro F, Müllhaupt B, Semela D   +73 more
core   +1 more source

Identification of (20R)‐protopanaxadiol from Panax ginseng as a novel anti‐SARS‐CoV‐2 compound

FEBS Open Bio, EarlyView.
We established a noninfectious BAC‐based SARS‐CoV‐2 replicon that enables antiviral screening under BSL‐2 conditions. Using this platform, we screened 373 food‐derived compounds and identified (20R)‐protopanaxadiol from Panax ginseng as a novel inhibitor of SARS‐CoV‐2 RNA replication, highlighting the value of safe replicon systems for antiviral ...
Midori Takeda, Natsue Maezono, Rina Uchikoshi, Nobuyuki Kato, Masanori Ikeda   +4 more
wiley   +1 more source

What is Hep C?

, 2023
Hepatitis C is a virus that causes Hepatitis. There are 4 different types of Viral Hepatitis A,B,C,D and E. Hepatitis C is an infection of th liver caused by the Hepatitis C Virus. The virus gets into your body through infected blood.

core  

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Costs of Hepatitis C [PDF]

Archives of Internal Medicine, 2001
To estimate the direct and indirect costs of the hepatitis C virus (HCV) in the United States in 1997.Aggregation and analysis of national data sets collected by the National Center for Health Statistics, the Health Care Financing Administration, and other government bureaus and private firms.
J P, Leigh, C L, Bowlus, B N, Leistikow, M, Schenker   +3 more
openaire   +2 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Diagnoses of, and deaths from, severe liver disease due to hepatitis C in England between 2000 and 2005 estimated using multiple data sources. [PDF]

, 2008
Matching individuals reported to a sentinel surveillance scheme for hepatitis C between 2000 and 2005 to individuals with a hospital episode for hepatitis C-related liver disease in the same hospitals, we estimated that the number of cases of hepatitis C-
Mann, AG, Balogun, MA, Brant, LJ, Costella, A, Harris, HE, Ramsay, ME, A. COSTELLA, H. E. HARRIS, M. A. BALOGUN, L. J. BRANT, M. E. RAMSAY, A. G. MANN   +11 more
core   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection.

, 2007
BACKGROUND: Two receptor chains, IL-10RA and IL-10RB, are known to mediate the functions of interleukin-10 (IL-10), which has been shown to be involved in the progression of persistent hepatitis C virus (HCV) infection. Little information is available on
Thursz, Mark, Hill, Adrian V, Zhang, Lyna, Thomas, Howard C, Hennig, Branwen J, Wright, Mark, Yee, Leland J, Frodsham, Angela J, Hellier, Simon, Knapp, Susanne   +9 more
core   +1 more source

Interferon signalling in the liver : implications for the natural course and therapy of hepatitis C [PDF]

, 2012
Hepatitis C virus is a global health concern, estimated to infect 2-3% of the world's population. Inter-individual differences in the course of infection and response to therapy, highlighted by recent genomewide association studies, point to the crucial ...
Makowska, Zuzanna
core   +1 more source